NEW STUDY: Resveratrol and Copper Trigger System-Level Collapse of Human Glioblastoma Aggressiveness in Just 12 Days
In one of the deadliest human cancers, cheap nutraceuticals produced coordinated suppression of tumor proliferation, cancer hallmarks, immune checkpoints, stemness, and activated intrinsic apoptosis.
Dandelion Root Extract Kills 95% of Cancer Cells In Vitro and Reduces Human Colon Tumor Growth by Over 90% in Mice — With Zero Toxicity
A peer-reviewed study finds that a common backyard plant selectively kills cancer cells while sparing normal cells, acting through multiple coordinated anti-cancer pathways.
THESE Foods STARVE Cancer (Scientific Proof) | Dr. William Li - YouTube
THESE Foods STARVE Cancer (Scientific Proof) | Dr. William Li📩 Join the Food as Medicine newsletter: https://news.angio.org/👉 Subscribe for more science-ba...
NEW STUDY: Intranasal Nano-Ivermectin Shrinks Brain Tumors by 70% Without Toxicity
Landmark preclinical study shows intranasal ivermectin nanocapsules safely shrink glioblastoma in animal models at doses lower than the approved human antiparasitic dose.
Repurposed Drugs in Oncology: Current State Of The Evidence And A Case Series In Metastatic Lung Cancer
A review of the existing evidence base for repurposing drugs to treat cancer, followed by a case series of five consecutive patients treated with combination repurposed drug protocols.
Chemotherapy Makes Cancer Worse: The Evidence They Tried to Hide
A suppressed 2017 Telegraph report, cutting-edge science, and decades of warnings from natural health advocates converge to reveal a devastating truth: the treatment fuels the disease.
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression | ACS Biomaterials Science & Engineering
Glioblastoma presents significant challenges in neuro-oncology due to its aggressive nature, drug resistance, and restrictions imposed by the blood–brain barrier. Ivermectin (IVM), known for its antiparasitic properties, has been highlighted as a promising treatment for tumors and an alternative therapy for glioma, although it exhibits low oral bioavailability. Therefore, we investigated the in vivo effect of IVM encapsulation in organic and inorganic nanosystems, first screened in vitro against different tumor cells and subsequently evaluated in vitro and in vivo glioma models. We produced IVM-loaded poly(ε-caprolactone) nanocapsules (IVM-NC) using the interfacial deposition method, and IVM-loaded nanostructured silica particles (IVM-MCM) by loading IVM into commercial MCM-41 silica using the incipient wetness method. IVM-NC had a nanometric size (190 nm), a unimodal size distribution (span <2), and a high encapsulation efficiency (100% at 1 mg/mL). IVM-MCM exhibited a well-organized hexagonal mesoporous structure and high drug loading (0.12 mg/mg). Nanoencapsulated IVM significantly reduced the viability of various cancer cell lines, particularly glioma cell lines, which led us to evaluate them in a preclinical glioma model. We implanted adult male Wistar rats with C6 cells. Intranasal delivery of IVM-NC (60 μg/rat/day for 10 days) resulted in a larger decrease in tumor size compared with the group treated with free IVM, along with histopathological improvements. Treatment with IVM-MCM did not decrease the tumor size. However, both treatments were well-tolerated, with no adverse effects on weight, biochemical, or hematological parameters, or lung histology. Furthermore, the effective equivalent dose of IVM (26 μg/kg) in the rat glioma model was lower than the approved human dose for parasitic infections. This study marks the first exploration of IVM delivery to the brain. In summary, nasal administration of nanoencapsulated IVM via nanocapsules presents a promising avenue for targeted therapy against glioblastoma, with potential implications for clinical translation.
Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol - ISOM
.
Introduction
Many theories exist regarding the origin of cancer, namely the metabolic theory (Seyfried & Chinopoulos, 2021), the somatic mutation theory (SMT) (Hanahan & Weinberg, 2000), the cancer stem cell theory (Capp, 2019), and the tissue organization theory (Soto & Sonnenschein, 2011). In a recently published study, a new concept was introduced the
Astounding suppressed medicine - Low Dose Naltrexone
Professor of Oncology, Angus Dalgleish gives vital information on a repurposed drug he uses for his cancer patients, given at a very low dose. This is Low Do...
NEWS: Midwestern Doctor joins the coordinated attack on Ivermectin, Fenbendazole and Mebendazole and Cancer patients who want to break away from Big Pharma
